Clay Siegall

The recent pressure on Seagen Inc.’s (NASDAQ: SGEN) stock may offer a nearer-term opportunity, but the biotech's position as an attractive strategic target is “too intriguing to ignore.” That's according to RBC Capital Markets analyst Gregory Renza who named Merck & Co...